MODIFIED RELEASE SYSTEM FOR THE ANTICHAGASTIC BENZNIDAZOLE USING LAPONITE AS A NANOCARRIER
Modified release; drug delivery; benznidazole; laponite; Eudragit Ⓡ S100
Benznidazole (BNZ) is a medicine used to treat Chagas disease, a neglected disease that kills thousands of people around the world. This substance has low solubility in the gastrointestinal tract, which leads to low bioavailability of the drug in the body. A convenient alternative to improving treatment efficiency is incorporating the drug into clays, forming a modified drug delivery system. This way, there are better therapeutic effects and milder side effects. In this work, BNZ was incorporated into laponite (LAP), a synthetic clay that has a disc shape with a large specific area and highly ionic regions, using the fusion method. In this way, by capillarity the drug was impregnated with LAP forming the hybrid (LAP + BNZ) which was coated with eudragit Ⓡ S100 to protect the drug from degradation in acidic pH, this protection was achieved through the solvent evaporation technique using ethanol. The resulting product was characterized by X ray Diffraction (XRD), X ray Fluorescence (XRF), Fourier Transform Infrared Spectroscopy (FTIR), Thermogravimetry (TG), Differential Scanning Calorimetry (DSC), Scanning Electron Microscopy with Energy Dispersive X ray Spectroscopy (SEM-EDS). Through a study simulating stomach and intestinal pH, it was possible to verify that the modified system was efficient in the controlled release of the drug benznidazole, which gradually released approximately 11.4% of the drug in the simulated stomach region, 23.8% in the first simulated intestinal region and 53.2% in the second simulated region, releasing 88.4% over 12h. The kinetic study showed that the model with the best fit was the Korsmeyer- Peppas model, controlled mainly by Case II diffusion.